PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 15607317-4 2005 The method was applied to study the alteration of BRCA1 gene expression after exposure to taxol, doxorubicin, 5-fluorouracil, etoposide or gamma irradiation in human MCF-7 breast cancer cells. Paclitaxel 90-95 BRCA1 DNA repair associated Homo sapiens 50-55 14559807-6 2003 In contrast, BRCA1 induces a >1000-fold increase in sensitivity to the spindle poisons, paclitaxel and vinorelbine. Paclitaxel 91-101 BRCA1 DNA repair associated Homo sapiens 13-18 12717416-0 2003 Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1. Paclitaxel 40-50 BRCA1 DNA repair associated Homo sapiens 8-13 12717416-7 2003 The BRCA1 mutation in SNU-251 cells inhibited BRCA1 subnuclear assembly for DNA-damage repair and increased cellular sensitivity to ionizing radiation and paclitaxel. Paclitaxel 155-165 BRCA1 DNA repair associated Homo sapiens 4-9 12717416-7 2003 The BRCA1 mutation in SNU-251 cells inhibited BRCA1 subnuclear assembly for DNA-damage repair and increased cellular sensitivity to ionizing radiation and paclitaxel. Paclitaxel 155-165 BRCA1 DNA repair associated Homo sapiens 46-51 12717416-10 2003 BRCA1 helps to mediate the resistance to both radiation and paclitaxel. Paclitaxel 60-70 BRCA1 DNA repair associated Homo sapiens 0-5 11562742-4 2001 The enhanced loss of BRCA1 protein by taxol, okadaic acid or nocodazole treatment was prevented by the proteasome inhibitors, while inhibition of other proteases was ineffective. Paclitaxel 38-43 BRCA1 DNA repair associated Homo sapiens 21-26 11641785-4 2001 Decreased expression of BRCA1 led to sensitivity to the DNA damaging agents cisplatin and etoposide, resistance to the microtubule-interfering agents (MIA) taxol and vincristine. Paclitaxel 156-161 BRCA1 DNA repair associated Homo sapiens 24-29 11593420-3 2001 Induction of BRCA1 in the presence of Taxol and Vincristine resulted in a dramatic increase in cell death; an effect that was preceded by an acute arrest at the G2/M phase of the cell cycle and which correlated with BRCA1 mediated induction of GADD45. Paclitaxel 38-43 BRCA1 DNA repair associated Homo sapiens 13-18 11593420-3 2001 Induction of BRCA1 in the presence of Taxol and Vincristine resulted in a dramatic increase in cell death; an effect that was preceded by an acute arrest at the G2/M phase of the cell cycle and which correlated with BRCA1 mediated induction of GADD45. Paclitaxel 38-43 BRCA1 DNA repair associated Homo sapiens 216-221 33859743-13 2021 DRD2 also promoted BrCa cells sensitivity to Paclitaxel. Paclitaxel 45-55 BRCA1 DNA repair associated Homo sapiens 19-23 25445425-0 2015 Triple negative breast cancer in BRCA1 mutation carriers with a complete radiologic response to neoadjuvant paclitaxel: a case report. Paclitaxel 108-118 BRCA1 DNA repair associated Homo sapiens 33-38 11295099-0 2001 Regulation of BRCA1 and BRCA2 transcript in response to cisplatin, adriamycin, taxol and ionising radiation is correlated to p53 functional status in ovarian cancer cell lines. Paclitaxel 79-84 BRCA1 DNA repair associated Homo sapiens 14-19 35105904-3 2022 Recently, the combination of carboplatin and paclitaxel is being recommended to these BRCA-mutated patients as neoadjuvant therapy. Paclitaxel 45-55 BRCA1 DNA repair associated Homo sapiens 86-90 33996534-9 2021 Our case demonstrated a favorable clinical activity and survival advantage of the combined cisplatin and nanoparticle albumin-bound paclitaxel, which might serve as a therapeutic option for the patient with BRCA-mutant pancreatic SCC. Paclitaxel 132-142 BRCA1 DNA repair associated Homo sapiens 207-211 33377156-4 2021 We describe the discovery and treatment of occult cancer at the edge of the left fimbria in a BRCA1 mutation carrier who had, just a short time previously, undergone neoadjuvant paclitaxel plus carboplatin (TC) chemotherapy for triple-negative breast cancer. Paclitaxel 178-188 BRCA1 DNA repair associated Homo sapiens 94-99 32861273-0 2020 Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Paclitaxel 31-41 BRCA1 DNA repair associated Homo sapiens 45-49 33319669-5 2021 PTX resistance pathways that involve major regulatory proteins/RNAs like RNF8/Twist/ROR1, TLR, ErbB3/ErbB2, BRCA1-IRIS, MENA, LIN9, MiRNA, FoxM1 and IRAK1 have expanded the complexity of resistance mechanisms, and brought newer insights for development of drug targets. Paclitaxel 0-3 BRCA1 DNA repair associated Homo sapiens 108-113 32194804-0 2020 Sensitization of Carboplatinum- and Taxol-Resistant High-Grade Serous Ovarian Cancer Cells Carrying p53, BRCA1/2 Mutations by Emblica officinalis (Amla) via Multiple Targets. Paclitaxel 36-41 BRCA1 DNA repair associated Homo sapiens 105-110 32724113-5 2020 The organoid that harboured the BRCA1 pathogenic variant (p.L63*) showed a higher sensitivity to PARP inhibitor, olaparib, as well as to platinum drugs compared to the other organoids, whereas an organoid derived from clear cell ovarian cancer was resistant to conventional drugs for ovarian cancer, namely platinum drugs, paclitaxel, and olaparib. Paclitaxel 323-333 BRCA1 DNA repair associated Homo sapiens 32-37 33457057-10 2019 Hypersensitivity reactions to paclitaxel occurred in 1 of 13 (7.7%) BRCA-mutated patients and 26 of 49 (53.1%) BRCA wild-type patients (p = .0039). Paclitaxel 30-40 BRCA1 DNA repair associated Homo sapiens 68-72 33457057-10 2019 Hypersensitivity reactions to paclitaxel occurred in 1 of 13 (7.7%) BRCA-mutated patients and 26 of 49 (53.1%) BRCA wild-type patients (p = .0039). Paclitaxel 30-40 BRCA1 DNA repair associated Homo sapiens 111-115 33457057-15 2019 The presence of BRCA mutations was not statistically significantly associated with a higher incidence of HSRs to carboplatin, but was statistically significant with regards to paclitaxel. Paclitaxel 176-186 BRCA1 DNA repair associated Homo sapiens 16-20 28604461-1 2017 OBJECTIVE: Serous adenocarcinomas that arise in patients with inherited mutations in the tumor suppressor genes BRCA1 and BRCA2 are initially well treatable with platinum/paclitaxel. Paclitaxel 171-181 BRCA1 DNA repair associated Homo sapiens 112-117 29189915-12 2018 Finally, paclitaxel and docetaxel achieved additive cell-killing effects with CNDAC at concentration ranges of the taxanes similar for both BRCA1/2 deficient and proficient OC cells. Paclitaxel 9-19 BRCA1 DNA repair associated Homo sapiens 140-147 27739325-0 2017 A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Paclitaxel 117-127 BRCA1 DNA repair associated Homo sapiens 131-136 25499884-0 2015 Carboplatin and taxol resistance develops more rapidly in functional BRCA1 compared to dysfunctional BRCA1 ovarian cancer cells. Paclitaxel 16-21 BRCA1 DNA repair associated Homo sapiens 69-74 27113739-0 2016 Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers. Paclitaxel 58-68 BRCA1 DNA repair associated Homo sapiens 108-113 27113739-1 2016 The purpose of this study was to assess pathological complete response and whether it serves a surrogate for survival among patients receiving neo-adjuvant doxorubicin-cyclophosphamide followed by paclitaxel for triple-negative breast cancer with respect to BRCA1 mutation status. Paclitaxel 197-207 BRCA1 DNA repair associated Homo sapiens 258-263 25499884-3 2015 We used a clinically relevant comparative selection strategy to develop novel chemoresistant cell lines which aim to investigate the mechanisms of resistance that arise from different exposures of carboplatin and taxol on cells having BRCA1 function (UPN251) or dysfunction (OVCAR8). Paclitaxel 213-218 BRCA1 DNA repair associated Homo sapiens 235-240 25499884-4 2015 Resistance to carboplatin and taxol developed quicker and more stably in UPN251 (BRCA1-wildtype) compared to OVCAR8 (BRCA1-methylated). Paclitaxel 30-35 BRCA1 DNA repair associated Homo sapiens 81-86 25499884-4 2015 Resistance to carboplatin and taxol developed quicker and more stably in UPN251 (BRCA1-wildtype) compared to OVCAR8 (BRCA1-methylated). Paclitaxel 30-35 BRCA1 DNA repair associated Homo sapiens 117-122 23964347-0 2013 Assessment of the Prognostic Value of Two Common Variants of BRCA1 and BRCA2 Genes in Ovarian Cancer Patients Treated with Cisplatin and Paclitaxel: A Gynecologic Oncology Group Study. Paclitaxel 137-147 BRCA1 DNA repair associated Homo sapiens 61-66 25583261-0 2015 BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers. Paclitaxel 34-44 BRCA1 DNA repair associated Homo sapiens 0-5 25583261-3 2015 Here we investigate the role of BRCA1-IRIS as a novel treatment target for TNBCs and their paclitaxel-resistant recurrences. Paclitaxel 91-101 BRCA1 DNA repair associated Homo sapiens 32-37 25583261-4 2015 METHODS: We analyzed the response of BRCA1-IRIS overexpressing normal mammary cells or established TNBC cells silenced from BRCA1-IRIS to paclitaxel in vitro and in vivo. Paclitaxel 138-148 BRCA1 DNA repair associated Homo sapiens 37-42 25583261-5 2015 We analyzed BRCA1-IRIS downstream signaling pathways in relation to paclitaxel treatment. Paclitaxel 68-78 BRCA1 DNA repair associated Homo sapiens 12-17 25583261-8 2015 RESULTS: We show that low concentrations of paclitaxel triggers BRCA1-IRIS expression in vitro and in vivo, and that BRCA1-IRIS activates two autocrine signaling loops (epidermal growth factor (EGF)/EGF receptor 1 (EGFR)-EGF receptor 2 (ErbB2) and neurogulin 1 (NRG1)/ErbB2-EGF receptor 3 (ErbB3), which enhances protein kinase B (AKT) and thus survivin expression/activation through promoting FOXO3a degradation. Paclitaxel 44-54 BRCA1 DNA repair associated Homo sapiens 64-69 25583261-10 2015 These events trigger the intrinsic and acquired paclitaxel resistance phenotype known for BRCA1-IRIS-overexpressing TNBCs. Paclitaxel 48-58 BRCA1 DNA repair associated Homo sapiens 90-95 25583261-11 2015 Inactivating BRCA1-IRIS signaling using a novel inhibitory mimetic peptide inactivates these autocrine loops, AKT and survivin activity/expression, in part by restoring FOXO3a expression, and sensitizes TNBC cells to low paclitaxel concentrations in vitro and in vivo. Paclitaxel 221-231 BRCA1 DNA repair associated Homo sapiens 13-18 25583261-13 2015 CONCLUSIONS: In addition to driving TNBC tumor formation, BRCA1-IRIS overexpression drives their intrinsic and acquired paclitaxel resistance, partly by activating autocrine signaling loops EGF/EGFR-ErbB2 and NRG1/ErbB2-ErbB3. Paclitaxel 120-130 BRCA1 DNA repair associated Homo sapiens 58-63 25481791-15 2015 INTERPRETATION: Olaparib plus paclitaxel and carboplatin followed by maintenance monotherapy significantly improved progression-free survival versus paclitaxel plus carboplatin alone, with the greatest clinical benefit in BRCA-mutated patients, and had an acceptable and manageable tolerability profile. Paclitaxel 30-40 BRCA1 DNA repair associated Homo sapiens 222-226 24847251-12 2014 The author believes that this case is the first report of a robust response to nab-paclitaxel monotherapy in triple-negative BRCA1-positive breast cancer, and that it supports further studies of nab-paclitaxel in this aggressive indication. Paclitaxel 83-93 BRCA1 DNA repair associated Homo sapiens 125-130 23462720-0 2013 BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study. Paclitaxel 109-119 BRCA1 DNA repair associated Homo sapiens 0-5 23462720-16 2013 Although these results merit validation in future studies, the results suggest that decreased BRCA1 expression predicts for improved response to cisplatin-based IP chemotherapy with cisplatin and paclitaxel. Paclitaxel 196-206 BRCA1 DNA repair associated Homo sapiens 94-99 23265709-0 2013 Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer. Paclitaxel 62-72 BRCA1 DNA repair associated Homo sapiens 16-21 23522120-4 2013 METHODS: We performed exome sequencing on the blood, primary tumor, omental metastasis and recurrence following therapy with carboplatin and paclitaxel, from a patient carrying a BRCA1 S1841R mutation. Paclitaxel 141-151 BRCA1 DNA repair associated Homo sapiens 179-184 19955925-0 2009 Does paclitaxel-carboplatin chemotherapy in a dose-dense regimen enhance survival of BRCA-related ovarian cancer patients? Paclitaxel 5-15 BRCA1 DNA repair associated Homo sapiens 85-89 21781528-1 2011 OBJECTIVE: To investigate the predictive value of breast cancer susceptibility gene 1 (BRCA1) and class IIIbeta-tubulin protein expression in tumor tissue for the efficacy of taxol and cisplatin combined chemotherapy (TP) in stage IIIB/IV non-small cell lung cancer (NSCLC) patients. Paclitaxel 175-180 BRCA1 DNA repair associated Homo sapiens 87-92 21296416-0 2011 BRCA1 suppresses the expression of survivin and promotes sensitivity to paclitaxel through the calcium sensing receptor (CaSR) in human breast cancer cells. Paclitaxel 72-82 BRCA1 DNA repair associated Homo sapiens 0-5 21296416-1 2011 Both BRCA1 and CaSR have been shown to suppress the expression of survivin and promote sensitivity to paclitaxel in human breast cancer cells. Paclitaxel 102-112 BRCA1 DNA repair associated Homo sapiens 5-10 21296416-3 2011 We found that mutant cells (harboring mutant BRCA1 with loss of BRCA1 expression) had a significant reduction in the expression of CaSR with a concurrent up-regulated expression of survivin and were resistant to paclitaxel by comparison to wild type cells (harboring wild type BRCA1 and expressing BRCA1). Paclitaxel 212-222 BRCA1 DNA repair associated Homo sapiens 45-50 21296416-4 2011 Knocking down the expression of BRCA1 in wild type cells resulted in a reduction in CaSR expression with a concurrent up-regulated expression of survivin and reduction in sensitivity to paclitaxel. Paclitaxel 186-196 BRCA1 DNA repair associated Homo sapiens 32-37 21296416-5 2011 Re-expression of BRCA1 in BRCA1 knocked-down wild type cells restored CaSR expression with a concurrent down-regulated expression of survivin and restoration of sensitivity to paclitaxel. Paclitaxel 176-186 BRCA1 DNA repair associated Homo sapiens 17-22 21296416-5 2011 Re-expression of BRCA1 in BRCA1 knocked-down wild type cells restored CaSR expression with a concurrent down-regulated expression of survivin and restoration of sensitivity to paclitaxel. Paclitaxel 176-186 BRCA1 DNA repair associated Homo sapiens 26-31 21296416-6 2011 Corollary, ectopic expression of BRCA1 in mutant cells induced CaSR expression, suppressed the expression of survivin and restored sensitivity to paclitaxel. Paclitaxel 146-156 BRCA1 DNA repair associated Homo sapiens 33-38 21296416-12 2011 We conclude, and report for the first time, that BRCA1 regulates the expression of CaSR and that it functions through CaSR in suppressing the expression of survivin and promoting sensitivity to paclitaxel. Paclitaxel 194-204 BRCA1 DNA repair associated Homo sapiens 49-54 19551867-5 2009 In BRCA1 knocked-down cells, the expression of survivin was significantly up regulated with a concurrent decrease in cellular sensitivity to paclitaxel. Paclitaxel 141-151 BRCA1 DNA repair associated Homo sapiens 3-8 19551867-7 2009 Cells harboring mutated BRCA1 also expressed a high level of survivin and were relatively resistant to paclitaxel by comparison to wild-type cells. Paclitaxel 103-113 BRCA1 DNA repair associated Homo sapiens 24-29 19551867-8 2009 Increase resistance to paclitaxel was due to an increase in the expression of survivin in both the BRCA1 knocked-down and mutant BRCA1 cells because knocking down survivin expression by siRNA restored sensitivity to paclitaxel. Paclitaxel 23-33 BRCA1 DNA repair associated Homo sapiens 99-104 19551867-8 2009 Increase resistance to paclitaxel was due to an increase in the expression of survivin in both the BRCA1 knocked-down and mutant BRCA1 cells because knocking down survivin expression by siRNA restored sensitivity to paclitaxel. Paclitaxel 23-33 BRCA1 DNA repair associated Homo sapiens 129-134 19551867-10 2009 Moreover, loss of BRCA1 expression or function leads to an increase in survivin expression and a reduction in chemosensitivity to paclitaxel. Paclitaxel 130-140 BRCA1 DNA repair associated Homo sapiens 18-23 23326344-2 2013 Breast cancer susceptibility gene 1 (BRCA1) expression has been found to switch the response to cisplatin- or paclitaxel-based chemotherapy. Paclitaxel 110-120 BRCA1 DNA repair associated Homo sapiens 37-42 19697632-0 2009 Repeat chemosensitivity of epithelial ovarian carcinoma in a BRCA1 mutation carrier to paclitaxel/platinum combination chemotherapy. Paclitaxel 87-97 BRCA1 DNA repair associated Homo sapiens 61-66 19442054-9 2009 We propose that BRCA1 should be the first of a panel of cellular markers to predict the inverse cisplatin/paclitaxel resistance phenotype. Paclitaxel 106-116 BRCA1 DNA repair associated Homo sapiens 16-21 18547621-10 2008 BRCA mutation analysis identified germline BRCA1 mutation for further testing and this xenograft showed a significant response to carboplatin/paclitaxel chemotherapy, including a decrease in tumor volume and proliferation but did not demonstrate a response to the poly (ADP-ribose) polymerase-1 inhibitor PJ34. Paclitaxel 142-152 BRCA1 DNA repair associated Homo sapiens 0-4 19697632-1 2009 We present here a case of a BRCA1 mutation carrier with repeat responsiveness of recurrent EOC to paclitaxel/platinum. Paclitaxel 98-108 BRCA1 DNA repair associated Homo sapiens 28-33 19697632-5 2009 In conclusion, recurrent EOC in BRCA1 mutation carriers may retain sensitivity to paclitaxel/platinum combination chemotherapy, and this combination could be therapy of first choice in this patient population. Paclitaxel 82-92 BRCA1 DNA repair associated Homo sapiens 32-37 19002265-2 2008 BRCA1 overexpression increases sensitivity to paclitaxel and docetaxel. Paclitaxel 46-56 BRCA1 DNA repair associated Homo sapiens 0-5 19690636-3 2007 To address if BRCA1 expression plays a role in the chemotherapeutic response, we analyzed the effect of BRCA1 suppression on the sensitivity to cisplatin and paclitaxel in ovarian cancer cells. Paclitaxel 158-168 BRCA1 DNA repair associated Homo sapiens 104-109 16982732-7 2006 Consistent with the reported platinum chemosensitivity in patients with Brca1-associated ovarian cancer, the Brca1-deficient OSE cells have increased sensitivity to the DNA-damaging agent cisplatin, whereas sensitivity to the microtubule poison paclitaxel is similar between Brca1 wild-type and Brca1-deficient cells. Paclitaxel 245-255 BRCA1 DNA repair associated Homo sapiens 109-114 16982732-7 2006 Consistent with the reported platinum chemosensitivity in patients with Brca1-associated ovarian cancer, the Brca1-deficient OSE cells have increased sensitivity to the DNA-damaging agent cisplatin, whereas sensitivity to the microtubule poison paclitaxel is similar between Brca1 wild-type and Brca1-deficient cells. Paclitaxel 245-255 BRCA1 DNA repair associated Homo sapiens 109-114 16982732-7 2006 Consistent with the reported platinum chemosensitivity in patients with Brca1-associated ovarian cancer, the Brca1-deficient OSE cells have increased sensitivity to the DNA-damaging agent cisplatin, whereas sensitivity to the microtubule poison paclitaxel is similar between Brca1 wild-type and Brca1-deficient cells. Paclitaxel 245-255 BRCA1 DNA repair associated Homo sapiens 109-114 16639080-0 2006 BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Paclitaxel 87-97 BRCA1 DNA repair associated Homo sapiens 0-5 16639080-3 2006 In this report, we studied BRCA1 contribution to paclitaxel response in MCF-7 breast cancer cells. Paclitaxel 49-59 BRCA1 DNA repair associated Homo sapiens 27-32 16639080-4 2006 We show that MCF-7 cells transfected with BRCA1 siRNA display a significant increase in resistance to paclitaxel compared with the control cells. Paclitaxel 102-112 BRCA1 DNA repair associated Homo sapiens 42-47 16639080-5 2006 We next demonstrate that downregulation of BRCA1 reduces the mitotic index and triggers premature cyclin B1 degradation and decrease in Cdk1 activity following paclitaxel treatment, suggesting that BRCA1 downregulation results in precocious inactivation of the spindle checkpoint. Paclitaxel 160-170 BRCA1 DNA repair associated Homo sapiens 43-48 16639080-5 2006 We next demonstrate that downregulation of BRCA1 reduces the mitotic index and triggers premature cyclin B1 degradation and decrease in Cdk1 activity following paclitaxel treatment, suggesting that BRCA1 downregulation results in precocious inactivation of the spindle checkpoint. Paclitaxel 160-170 BRCA1 DNA repair associated Homo sapiens 198-203 16639080-7 2006 Furthermore, we show that BRCA1 up-regulates the expression of the protein kinase BubR1, essential component of the functional spindle checkpoint, whose downregulation is known to result in paclitaxel resistance in MCF-7 cells. Paclitaxel 190-200 BRCA1 DNA repair associated Homo sapiens 26-31 16639080-8 2006 Altogether, our findings support the notion that downregulation of BRCA1 expression mediates paclitaxel resistance through premature inactivation of spindle checkpoint in MCF-7 breast cancer cells. Paclitaxel 93-103 BRCA1 DNA repair associated Homo sapiens 67-72